PBYI

PUMA BIOTECHNOLOGY INC

8.14

USD

-0.25

-3.04%

Nov 10, 15:59 UTC -5

Closed

After-Market

8.14

0.00

0.00%

PUMA BIOTECHNOLOGY INC (PBYI) Earnings

PBYI Earnings Reports

Positive Surprise Ratio

PBYI beat 33 of 44 last estimates.

75%

Next Report

Date of Next Report

Feb 24, 2027

Estimate for Q4 26 (Revenue/ EPS)

$68.54M

$0.23

Implied change from Q3 26 (Revenue/ EPS)

+24.40%

+53.33%

Implied change from Q4 25 (Revenue/ EPS)

-9.21%

-11.54%

PUMA BIOTECHNOLOGY INC earnings per share and revenue

On Nov 05, 2026, PBYI reported earnings of 0.15 USD per share (EPS) for Q3 26, beating the estimate of 0.09 USD, resulting in a 63.40% surprise. Revenue reached 55.10 million, compared to an expected 58.65 million, with a -6.05% difference. The market reacted with a -15.56% price change (close before vs. close after earnings).

Looking ahead to Q4 26, 3 analysts forecast an EPS of 0.23 USD, with revenue projected to reach 68.54 million USD, implying an increase of 53.33% EPS, and increase of 24.40% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Kura Oncology, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.83

Actual

-$0.78

Surprise

+7.00%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.63

Actual

-$0.73

Surprise

-14.53%

Autolus Therapeutics plc - ADR

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.21

Surprise

-27.20%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.03

Actual

$0.05

Surprise

+265.02%

PepGen Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.19%

Humacyte, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.07

Surprise

+22.91%

Seer, Inc. Class A Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.25

Actual

-$0.25

Surprise

+1.96%

Scholar Rock Holding Corporation Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.86

Actual

-$0.81

Surprise

+6.18%

TELA Bio, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.13

Surprise

+20.54%

Atossa Therapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.90

Actual

-$0.56

Surprise

+38.31%

FAQ

What were PUMA BIOTECHNOLOGY INC's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, PUMA BIOTECHNOLOGY INC reported EPS of $0.15, beating estimates by 63.4%, and revenue of $55.10M, -6.05% below expectations.

How did the market react to PUMA BIOTECHNOLOGY INC's Q3 2026 earnings?

The stock price moved down -15.56%, changed from $9.77 before the earnings release to $8.25 the day after.

When is PUMA BIOTECHNOLOGY INC expected to report next?

The next earning report is scheduled for Feb 24, 2027.

What are the forecasts for PUMA BIOTECHNOLOGY INC's next earnings report?

Based on 3 analysts, PUMA BIOTECHNOLOGY INC is expected to report EPS of $0.23 and revenue of $68.54M for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.